[EN] COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE<br/>[FR] COMPOSÉS INTERAGISSANT AVEC LA SUPERFAMILLE RAS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE CANCERS, DE MALADIES INFLAMMATOIRES, DE RASOPATHIES ET DE MALADIES FIBROTIQUES
申请人:SHY THERAPEUTICS LLC
公开号:WO2018237084A1
公开(公告)日:2018-12-27
Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.
THIENYL [3,2-D] PYRIMIDIN-4-ONE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
申请人:SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
公开号:US20140323466A1
公开(公告)日:2014-10-30
Disclosed are new thienyl[3,2-d]pyrimidin-4-one compounds shown as the general formula (I), preparation method, pharmaceutical compositions and pharmacological use thereof. The compounds are strong DPPIV (dipeptide peptidase IV) inhibitors and can treat type II diabetes through well inhibiting DPPIV indirectly increasing the content of GLP-1 in vivo and inducing a series of physiological actions in vivo. Therefore, the compounds could be developed as new promising drugs for treating diabetes.
Compounds for the treatment of cancer and inflammatory disease
申请人:SHY Therapeutics LLC
公开号:US10221191B2
公开(公告)日:2019-03-05
Provided herein are compounds that inhibit the phosphorylation of MAPK and thus are useful in compositions and methods for treating cancer and inflammatory disease.
本文提供的化合物可抑制 MAPK 磷酸化,因此可用于治疗癌症和炎症性疾病的组合物和方法中。
Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
申请人:SHY Therapeutics LLC
公开号:US10588894B2
公开(公告)日:2020-03-17
Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a novel method for assaying such compositions.